WeVote
Log In

Bill

Bill

S 4045

Relates to requiring the installation of intelligent speed assistance devices for repeated violation of maximum speed limits

2025 Regular Session Introduced by Jamaal Bailey and 29 co-sponsors

Requires testing seized substances for xylazine, builds a statewide database for law enforcement, and feeds findings into public health dashboards to boost overdose surveillance.

REFERRED TO TRANSPORTATION
0
WeVote Research Nonpartisan
Bill Summary · S 4045

Summary — S.4045 (Introduced Version / 2025)

Note on title discrepancy: The bill number S.4045 is presented with a title referring to “intelligent speed assistance devices,” but the text of the introduced version and amendment language actually amends P.L.2019, c.504 (C.52:17B‑246) to expand drug surveillance and testing requirements to include xylazine. This summary is based on the bill text as provided (drug testing / xylazine), not the unrelated title.

Purpose

To expand the State’s existing drug‑monitoring program (established under P.L.2019, c.504) so that controlled dangerous substances seized by law enforcement are routinely tested for the presence of xylazine (in addition to fentanyl), to compile and share those results statewide, and to feed the findings into the State’s public health overdose data systems.

Key provisions

  • Amends Section 1 of P.L.2019, c.504 (C.52:17B‑246).
  • Requires the Attorney General to maintain the existing multi‑jurisdictional drug activity monitoring program and to require law enforcement‑seized controlled substances be tested for xylazine in accordance with protocols established by the Division of State Police.
  • Testing protocols: substances shall be tested using forensic laboratory analysis techniques the Division of State Police determines appropriate to detect fentanyl, xylazine, or other potentially lethal substances.
  • Reporting and database:
    • Results (presence/content of fentanyl or xylazine and related information) must be reported to the Attorney General in a timely manner.
    • Information will be compiled into a continuously updated database accessible to all New Jersey law enforcement agencies.
    • The database must include other relevant information received by the Division of State Police forensic laboratory and the Chief State Medical Examiner.
  • Public health integration: Information pertaining to fentanyl and xylazine (seizures, overdoses, related deaths) must be submitted to the Department of Health for inclusion in the New Jersey State Assessment Data System and the Overdose Data Dashboard maintained by the Center for Health Statistics and Informatics.
  • Definition: Provides a broad statutory definition of “xylazine,” covering xylazine and specified related compounds, salts, isomers and metabolites.
  • Effective date: the act takes effect immediately upon enactment.

Who is affected

  • Division of State Police forensic laboratory and Chief State Medical Examiner (testing and reporting responsibilities).
  • Attorney General’s office (program oversight and database compilation).
  • All law enforcement agencies in New Jersey (required submissions; access to the database).
  • Department of Health and public‑health surveillance systems (must incorporate data).
  • Communities, harm‑reduction providers, public health planners and policymakers (benefit from improved drug supply intelligence).

Potential impact and considerations

  • Public health: improved detection and surveillance of xylazine in the illicit drug supply may enable faster public‑health alerts, targeted prevention, and improved overdose response planning.
  • Law enforcement & forensic capacity: increased testing requirements may strain forensic laboratory resources and create additional costs and turnaround‑time considerations (costs not specified in bill).
  • Data sharing: centralizing and continuously updating a statewide database increases law enforcement and public‑health situational awareness but may raise operational and privacy implementation questions to be managed in practice.

Legislative status (select)

  • Introduced: January 14, 2025.
  • Passed Senate: June 12, 2025.
  • Delivered to Assembly and referred to Assembly Transportation Committee (June 12, 2025).
  • Primary sponsor: Andrew Gounardes; numerous cosponsors listed.
  • Companion bill: A.2299 (assembly).

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.